Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

9 Months Ended

Aug. 31, 2024

As of August 31, 2024 and November 30, 2023, the note payable obligation was as follows:


	August 31, 2024			November 30, 2023
Note payable - Susser	$	8,658,654		$	8,765,082
Unamortized debt issuance costs - Susser		(153,437	)		(169,404	)
Net note payable	$	8,505,217		$	8,595,678
Current portion of note payable	$	174,587		$	165,641
Long-term note payable, net of debt issuance costs		8,330,630			8,430,037
Total	$	8,505,217		$	8,595,678

Interest expense on the note payable for the three and nine months ended August 31, 2024 and 2023 was as follows:


	For the three months ended		For the nine months ended
	August 31, 2024		August 31, 2024
Interest expense on notes payable - Susser	$	254,758	$	301,924
Debt issuance costs - Susser		5,297		5,297
Total interest expense	$	260,055	$	307,221


	For the three months ended		For the nine months ended
	August 31, 2023		August 31, 2023
Interest expense on notes payable - Susser	$	200,638	$	607,319
Debt issuance costs - Susser		5,396		16,258
Total interest expense	$	206,034	$	623,577